logo
Plus   Neg
Share
Email

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shortly after announcing a racial bias training for the staff, Starbucks revealed its changed policy of allowing anyone to use its spaces, rest rooms, cafes and patios even without buying anything from the stores. The new policy will be consistent all across U.S. stores. Tesla Inc.'s CEO Elon Musk has revealed new specifications and options for its Model 3 electric car, including a high-end version of the sedan that will cost around $78,000. In a series of posts on Twitter Saturday night, Musk said that the Model 3 will be available in two versions, with dual motors and all-wheel drive in July. Musk also made an announcement regarding a new service program. Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles.
Follow RTT